Highlights

  • China study involving nearly 15,000 women strengthens TruScreen’s case for nationwide adoption.
  • India regulatory approval is expected within three to six months, opening a major growth market.
  • Three UNITAID applications could contribute up to NZ$4 million in annual revenue between FY2028 and FY2030.

Overview

TruScreen Group Limited (NZX:TRU) has provided a significant update on its global expansion strategy as demand grows for accessible cervical cancer screening solutions. The company continues to strengthen its presence across Asia, Africa, Europe, and Central Asia, supported by clinical studies, regulatory approvals, distributor partnerships, and collaborations with governments and global health organizations. With countries working toward the World Health Organization’s 2030 cervical cancer screening targets, TruScreen is positioning its AI-enabled technology as a practical solution for low- and middle-income regions where traditional laboratory-based screening remains limited. Recent developments in China, India, Nigeria, Zimbabwe, and several Southeast Asian markets highlight growing momentum that could drive future revenue growth and expand access to life-saving screening programs worldwide.

How Could China and India Become Major Growth Engines for TruScreen?

China and India remain two of TruScreen’s most important opportunities due to their large cervical cancer burden and low screening coverage in many regions. In China, a landmark clinical study involving nearly 15,000 women demonstrated stronger sensitivity and specificity compared to traditional screening methods, supporting efforts to secure an Expert Consensus endorsement from leading medical bodies. Such recognition could accelerate adoption across public and private healthcare systems. Meanwhile, in India, regulatory approval is anticipated within the next three to six months following product evaluation activities. With more than 127,000 new cervical cancer cases annually and extremely low national screening rates, India represents a substantial long-term commercial opportunity.

Why Is TruScreen Accelerating Expansion Across Africa, Southeast Asia, and Europe?

Beyond China and India, TruScreen is rapidly expanding into multiple high-potential regions through distributor appointments, pilot studies, and government engagement. In Africa, programs are progressing in Zimbabwe, Nigeria, and South Africa, where cervical cancer rates remain among the highest globally. The company is also pursuing opportunities through UNITAID-funded initiatives and partnerships with international health organizations. In Southeast Asia, progress continues in Vietnam, Thailand, Malaysia, Singapore, Bangladesh, and Sri Lanka through registrations and healthcare partnerships. Meanwhile, pilot studies and product registrations across Uzbekistan, Central Asia, and Italy are expected to strengthen TruScreen’s clinical credibility and support broader adoption in both emerging and developed healthcare markets.